Почетна › Многи мијелом › Охајо › Cincinnati
Kliničke studije za Многи мијелом u gradu Cincinnati, OH
17 studija za Многи мијелом traži učesnike na lokacijama u gradu Cincinnati i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Тражи се учесникФаза 3
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- TriHealth Cancer Institute-Good Samaritan Hospital, Cincinnati
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
- и још 4
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Тражи се учесникФаза 3
- TriHealth Cancer and Blood Institute, Cincinnati
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 1
- University Of Cincinnati Medical Center /ID# 251746, Cincinnati
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Тражи се учесникФаза 3
- The Christ Hospital Cancer Center, Cincinnati
- Oncology Hematology Care, Cincinnati
- University of Cincinnati, Cincinnati
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Тражи се учесникФаза 1
- The Christ Hospital Cancer Center-Research, Cincinnati
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Тражи се учесникФаза 1/2
- Oncology Hematology Care - Blue Ash /ID# 272918, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Тражи се учесникФаза 3
- University of Cincinnati Medical Center, Cincinnati
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 2
- Oncology Hematology Care, Cincinnati
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Тражи се учесникФаза 3
- Research Site, Cincinnati
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Тражи се учесникФаза 3
- The Christ Hospital, Cincinnati
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Тражи се учесникФаза 2
- University of Cincinnati Medical Center, Cincinnati
- West Chester Hospital, West Chester · 15 ми удаљено
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Тражи се учесникФаза 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Bethesda North Hospital, Cincinnati
- TriHealth Cancer Institute-Westside, Cincinnati
- и још 1
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Тражи се учесникФаза 3
- Research Site, Cincinnati
- Research Site, Montgomery · 11 ми удаљено
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Тражи се учесникФаза 3
- Good Samaritan Hospital - Cincinnati, Cincinnati
- Oncology Hematology Care Inc-Kenwood, Cincinnati
- Bethesda North Hospital, Cincinnati
- и још 2
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Тражи се учесникФаза 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
Тражи се учесникФаза 2
- Oncology Hematology Care, Cincinnati
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Тражи се учесникФаза 1
- Oncology Hematology Care, Inc, Cincinnati
Studije za Многи мијелом u drugim gradovima
- New York City, NY59 студија
- Boston, MA45 студија
- Atlanta, GA42 студија
- Houston, TX39 студија
- Durham, NC36 студија
- Nashville, TN31 студија
- Denver, CO26 студија
- St. Louis, MO26 студија
- Rochester, MN25 студија
- Columbus, OH25 студија
- Chicago, IL24 студија
- Milwaukee, WI23 студија
Ostale studije u gradu Cincinnati
- Немалоклетни карцином плућа31 студија
- Рак (све врсте)26 студија
- Рак дојке24 студија
- Затајење срца22 студија
- Метастатски карцином21 студија
- Колоректални карцином20 студија
- Гојазност20 студија
- Akutna mijeloidna leukemija20 студија
- Рак простате19 студија
- Рак јајника18 студија
- Рак плућа18 студија
- Кардиоваскуларне болести16 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.